drugset / Trial / NCT04412395

Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease

NCT04412395

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients. The study was approved by the ethical committee of the Egyptian Center for Research and Regenerative Medicine in 11-5-2020.

Timeline

Start
2022-02-01
Primary completion
2022-08-01
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactoferrin Protein / enzyme biologic 1200 mg Oral